Fundraising FoxBiotechnology Value Fund — 2024 Investments
7 investments dated 2024 · listed companies and verified rows first · show all
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Adrian Gottschalk(President and Chief Executive Officer)
Co-investorsFlagship PioneeringXeraya CapitalDeerfield Management Company
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
.png)
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonDelos CapitalRA CapitalSoleus Capital
Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule therapies for obesity and other metabolic disorders.
BiotechHealthtechLongevityBoulder, US
Nicholas Traggis(Executive Officer, Director)
BoardKyle Lefkoff(Director)inDavid Snitman(Director)William S. Marshall(Director)John Orwin(Director)
Co-investorsColorado BioScience AssociationBoulder Ventures
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.
AI & Machine LearningBiotechMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Co-investorsJDRF T1D FundNewpath Partners
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongitude CapitalLongwood Fund+2 more
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in
BoardChau Khuong(Director)inChristina Takke(Director)Steven Prelack(Director)
Co-investorsRidgeback CapitalFrazier Life SciencesOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.